Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Go back to Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer| (NASDAQ: ARVN) | Delayed: 8.25 -0.06 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.31 | 52 Week High | $ | |||
| Open | $8.29 | 52 Week Low | $ | |||
| Day High | $8.35 | P/E | N/A | |||
| Day Low | $8.19 | EPS | $ | |||
| Volume | 163,123 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 27.45 -0.19 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.64 | 52 Week High | $37.39 | |||
| Open | $27.64 | 52 Week Low | $28.25 | |||
| Day High | $27.66 | P/E | 16.64 | |||
| Day Low | $27.34 | EPS | $1.65 | |||
| Volume | 10,416,911 | |||||
